Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nevirapine Mechanism on HDL in HIV+
NCT00144261Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2003
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of nevirapine in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage change of fractional synthetic rate (FSR) of Apo A-1 at 6 weeks and Percentage change of flow mediated dilatation (FMD) at 24 weeks. Started Nov 2003; status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00144261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144261.